Blog
RSS FeedPosted by Michael Wonder on 27 Sep 2018
Draft NICE decision rejects Respreeza for incurable, genetic disorder
27 September 2018 - NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in ...
Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of ...
Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft ...
Posted by Michael Wonder on 17 Sep 2018
Patients with high-risk skin cancer have new treatment option
17 September 2018 - Hundreds of patients with a type of advanced skin cancer are set to benefit from a new ...
Posted by Michael Wonder on 10 Sep 2018
NICE turns down Opdivo for adjuvant melanoma therapy
10 September 2018 - BMS drug currently only licensed treatment in this setting. ...
Posted by Michael Wonder on 10 Sep 2018
Roche faces UK pricing row over multiple sclerosis drug Ocrevus
10 September 2018 - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible ...
Posted by Michael Wonder on 10 Sep 2018
MS Society launches petition against NICE’s rejection of Ocrevus
10 september 2018 - The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, ...
Posted by Michael Wonder on 05 Sep 2018
NICE u-turn approves funding for rare disease therapy Crysvita
5 September 2018 - NICE has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the ...
Posted by Michael Wonder on 04 Sep 2018
Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
4 September 2018 - NICE quibbled with Merck's methodology for demonstrating the cost effectiveness of Keytruda in treating Hodgkin lymphoma patients ...
Posted by Michael Wonder on 29 Aug 2018
Cancer charities dismayed after ‘new generation’ therapy rejected as too expensive
29 August 2018 - A NICE committee said the cost of the drug was “too high for it to be considered ...
Posted by Michael Wonder on 28 Aug 2018
Cabometyx gets NICE recommendation in renal cell carcinoma
24 August 2018 - French drugmaker Ipsen that it has received a recommendation from NICE for National Health Service funding ...
Posted by Michael Wonder on 28 Aug 2018
Feedback encouraged to allow use of life extending treatment on NHS for those with blood cancer
28 August 2018 - CAR-T considered to be an exciting innovation which can cure some patients but very expensive. ...
Posted by Michael Wonder on 28 Aug 2018
NICE says ‘no’ to Gilead's Yescarta in draft guidelines
28 August 2018 - NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines ...
Posted by Michael Wonder on 23 Aug 2018
Sobi secures NHS reimbursement for Ravicti
23 August 2018 - Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti ...
Posted by Michael Wonder on 17 Aug 2018
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 August 2018 - NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used ...